Clinical trials: Antiviral Treatment
Hepatocellular Carcinoma
Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication
Although it is commonly accepted that antiviral therapy should be commenced before or during hepatocellular carcinoma (HCC) treatment if the patients have high viral loads and elevated ALT or total bilirubin values with signs of…
- Trial name
- NCT01894269
- Testing
- Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Respiratory Viral Infection, Antiviral Treatment
An Open Label Study in Adults to Test the Efficacy of Mitoquinone/Mitoquinol Mesylate to Prevent Severe Viral Illness
Open label clinical trial of persons (adults) that will determine the safety and efficacy of the diet supplement oral mitoquinone/mitoquinol mesylate (Mito-MES) to prevent the development and progression of severe viral…
- Conditions
- Respiratory Viral Infection, Antiviral Treatment, COVID-19
- Trial name
- NCT05381454
- Testing
- Mitoquinone/mitoquinol mesylate
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Chronic Hepatitis B
The Study on Optimal Treatment and Clinical Outcome of Chronic Hepatitis B Patients With Inactive Hypoviremia
Chronic hepatitis B seriously endangers the health of our people, especially the occurrence of HCC, which brings huge economic burden and life threat to our people. 84% - 92% of HCC in China is related to chronic HBV infection.
- Trial name
- NCT05357235
- Testing
- PEG-IFN
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Beijing Ditan Hospital
Children Diagnosed With HMFD, Propolis Antiviral Activity
Propolis as a Treatment Option for Hand Foot and Mouth Disease
Hand foot and mouth disease (HFMD) is a frequently self-limited viral infectious disease in children with no specific antiviral treatment option.
- Trial name
- NCT06455007
- Testing
- Propolis
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Murat Sutcu
Hepatitis C
ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings
The overall goals of the ETHOS II Project are to enhance hepatitis C virus (HCV) care in drug treatment clinics and needle and syringe programs (NSPs) in New South Wales and Australia, and to develop a translational framework for…
- Trial name
- ETHOS II (NCT03685045)
- Testing
- Campaign days
- Where
- 32 sites in Australia
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Cytomegalovirus Retinitis, HIV Infections
A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure
To examine the usefulness and safety of the antiviral drug foscarnet in treating AIDS patients with cytomegalovirus (CMV) infection that is causing sight-threatening inflammation of the retina in one or both eyes (CMV retinitis).
- Trial name
- NCT00000691
- Testing
- Foscarnet sodium
- Where
- 11 sites in United States
- Volunteers
- 156 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.
Evaluation of safety and efficacy of Tipranavir (TPV) boosted with Ritonavir (RTV) versus an active control arm (Lopinavir / RTV) in antiretroviral (ARV) therapy naïve HIV-1 infected patients
- Trial name
- NCT00144105
- Testing
- TPV500mg/RTV200mgBID, TPV500mg/RTV100mgBID, LPV400mg/RTV100mgBID
- Where
- 81 sites in Argentina, Australia and 13 more
- Volunteers
- 562 people
- Sponsor
- Boehringer Ingelheim
COVID-19, Immunodeficiency
OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial
The overall purpose of the trial is to evaluate the efficacy and safety of possible combination antiviral therapy DAA (remdesivir + nirmatrelvir/r)∞ versus the reference monotherapy (nirmatrelvir/r alone) and to assess the…
- Trial name
- OPTICOV (NCT05587894)
- Testing
- Paxlovid 5 days, Paxlovid 10 days, Veklury
- Where
- 18 sites in France, Italy and 1 more
- Volunteers
- 256 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to add 141W94 to an anti-HIV regimen that includes retrovir plus epivir.
- Trial name
- NCT00002195
- Testing
- Amprenavir, Lamivudine, Zidovudine
- Where
- 9 sites in United States
- Volunteers
- 290 people
- Sponsor
- Glaxo Wellcome
Cytomegalovirus Retinitis, HIV Infections
An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients
To evaluate the safety and efficacy of foscarnet induction therapy for treatment of AIDS patients experiencing their first episode of cytomegalovirus (CMV) retinitis.
- Trial name
- NCT00002039
- Testing
- Foscarnet sodium
- Where
- United States
- Sponsor
- Astra USA
Chronic Hepatitis C (HCV)
Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects
This is a proof-of-concept study which will provide data about the safety and antiviral activity of several doses of the investigational drug IDX184 given for 3 days in treatment-naive HCV genotype 1-infected subjects so that…
- Trial name
- NCT00807001
- Testing
- IDX184
- Volunteers
- 41 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Pharmacokinetics
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients
The current Standard of Care (SOC) for chronic HCV infection, which is pegylated interferon-alfa as combination therapy with ribavirin for 24-48 weeks of treatment, is effective in only part of the patients and is often…
- Trial name
- NCT00947349
- Testing
- ribavirin (RBV), pegylated interferon (PegIFN) alfa-2a, BI 201335 NA high
- Where
- 3 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Chronic Hepatitis B
The Study of Short-range Antiviral Treatment During Pregnancy to Block Mother-to-child Transmission of Hepatitis B Virus and Withdrawal Time
Pregnant women carry high HBV DNA loads before delivery, which is the most important factor leading to mother-to-child transmission of HBV.
- Trial name
- NCT03209908
- Testing
- Tenofovir Disoproxil Fumarate
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Beijing Ditan Hospital
Monkeypox, Mpox
Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease
The overall purpose of this study is to evaluate whether tecovirimat is an efficient and safe antiviral in the treatment of monkeypox in adults and adolescents (14 years old and older).
- Trial name
- UNITY (NCT05597735)
- Testing
- Tecovirimat
- Where
- 12 sites in Argentina, Brazil and 1 more
- Volunteers
- 480 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Healthy Volunteers
Nasal Residency of HEX17
This Phase 1 study will evaluate HEX17, an investigational antiviral nasal spray, in healthy adult volunteers. The study has two parts.
- Trial name
- NCT07898306
- Testing
- HEX17
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Pneumagen Ltd, a subsidiary of NorthLinks Bio
Infection, Human Immunodeficiency Virus
Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)
The purpose of this randomized, double-blinded study is to test the safety of GSK1265744 and how well it works on reducing the amount of HIV in the blood.
- Trial name
- NCT00920426
- Testing
- GSK1265744 30mg, GSK1265744 5mg
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- ViiV Healthcare
Hepatitis B, Chronic
Clinical and Basic Research of ETV Plus GM-CSF in Chronic Hepatitis B Patients
Previous studies indicated that Granulocyte Macrophage-colony Stimulating Factor (GM-CSF) could improve survival rate in patients with acute liver failure and obtain higher HBsAg seroconversion rate when in combination with…
- Trial name
- NCT03164889
- Testing
- Granulocyte Macrophage-colony Stimulating Factor, Entecavir
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Beijing 302 Hospital
Hepatitis C, Chronic
GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection
This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared with GS-5885, GS-9451 with Tegobuvir or RBV in Treatment-Experienced Subjects with Chronic Genotype…
- Trial name
- NCT01435226
- Testing
- GS-5885, GS-9451, tegobuvir
- Where
- 51 sites in United States, Germany
- Volunteers
- 170 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)
This is a multicenter, randomized, double-blind, parallel group, 48-week follow-up, Phase IIa clinical study. This study has been designed to evaluate the change in HBsAg (log10 IU/mL) after administration of hzVSF-v13 50 mg/dose…
- Trial name
- NCT05808335
- Testing
- Standard of care
- Where
- 4 sites in South Korea
- Volunteers
- 32 people
- Sponsor
- ImmuneMed, Inc.
Hepatitis C, Oxidative Stress
Blood Antioxidant Status in Chronic Hepatitis C Patients Before and After Antioxidant Supplementation: a Randomized Clinical Trial
The objective of the present study is to evaluate the antioxidant status in the blood of HCV patients treated with pegylated interferon (2a 1.5 ug/kg; 2b 180 ug) combined with ribavirin (1000 to 1250 mg) before and after…
- Trial name
- HepCAntSup (NCT00983164)
- Testing
- Antioxidant Supplementation
- Where
- 3 sites in Brazil
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Universidade do Sul de Santa Catarina